Trial Profile
This retrospective study evaluating Bevacizumab (Avastin) treatment for severe pulmonary hypertension and high Cardiac output failure secondary to liver involvement in patients with hereditary hemorrhagic telangiectasia.
Completed
Phase of Trial:
Phase IV
Latest Information Update: 17 Nov 2017
At a glance
- Drugs Bevacizumab (Primary)
- Indications Pulmonary hypertension
- Focus Therapeutic Use
- 17 Nov 2017 New trial record
- 24 Oct 2017 Results presented at The Liver Meeting 2017: 68th Annual Meeting of the American Association for the Study of Liver Diseases